Concepedia

M. Dar

MD

Statistics

Publications

5

Citations

95

H-Index

5

Active since

1997

Affiliations

Research Triangle Park Foundation(Current)

Duke Medical Center

Case Western Reserve University

M. Dar is an author at Research Triangle Park Foundation specializing in oncology, pharmacology, and oncology pharmacotherapy.

ORCID

Publications per year

1997–2006

5

Publications

5

Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.

Z. Abdel-Wahab, M. Dar, S. Osanto et al. · PubMed · 1997 · 30 citations

, , +16

Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors

A. Benjamin Suttle, H. Hurwitz, Afshin Dowlati et al. · Journal of Clinical Oncology · 2004 · 23 citations

, , +13

A Bayesian Population PK–PD Model of Ispinesib-induced Myelosuppression

Steven J. Kathman, Daphne Williams, Jeffrey P. Hodge et al. · Clinical Pharmacology & Therapeutics · 2006 · 20 citations

, , +17

Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors

A. Benjamin Suttle, H. Hurwitz, Afshin Dowlati et al. · Journal of Clinical Oncology · 2004 · 12 citations

, , +13

640 POSTER Phase I study of ispinesib (SB-715992), a kinesin spindle protein inhibitor, in combination with capecitabine in patients with advanced solid tumors

Jordi Rodón, Elizabeth Till, A. Patnaik et al. · European Journal of Cancer Supplements · 2006 · 10 citations

, , +11

1–5 of 5